Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis
Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis
复制标题
DOI：
10.1136/annrheumdis-2012-202297
复制
发表时间：
2013-02-01
影响因子：
27.4
通讯作者：
Aletaha, Daniel
中科院分区：
文献类型：
--
作者：
Boehler, Christoph;Radner, Helga;Aletaha, Daniel
目的探讨类风湿因子（RF）和抗瓜氨酸肽（ACPA）抗体在抗风湿药物治疗过程中的变化。方法收集患者治疗开始及治疗6个月后的临床及血清学资料。通过非参数测试，我们分析了两次就诊之间ACPA和RF水平的变化以及治疗反应的影响。此外，我们分析了潜在的影响因素，如疾病的慢性性、不同的治疗方法和18个月的趋势。结果纳入ACPA和RF阳性患者143例。6个月后的中位（第25 /75百分位）相对变化为：RF为-35.6% (-63.3;-8.3)，ACPA为-15.2% （-40.0;10.0）
Objective To investigate changes of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) during therapy with disease modifying antirheumatic drugs.Methods We obtained clinical and serological data of patients from the treatment start and after 6 months of therapy. With non-parametric tests, we analysed changes of ACPA and RF levels between the two visits and the influence of treatment response. Furthermore, we analysed potential influential factors as disease chronicity, different therapeutics and the trend over 18 months.Results 143 ACPA and RF positive patients were included. The median (25th/75th percentile) relative changes after 6 months were -35.6% (-63.3; -8.3) for RF and -15.2% (-40.0; 10.0) for ACPA (p